|
|
|
|
Search: 
Latin American Herald Tribune
Venezuela Overview
Venezuelan Embassies & Consulates Around The World
Sites/Blogs about Venezuela
Venezuelan Newspapers
Facts about Venezuela
Venezuela Tourism
Embassies in Caracas

Colombia Overview
Colombian Embassies & Consulates Around the World
Government Links
Embassies in Bogota
Media
Sites/Blogs about Colombia
Educational Institutions

Stocks

Commodities
Crude Oil
US Gasoline Prices
Natural Gas
Gold
Silver
Copper

Euro
UK Pound
Australia Dollar
Canada Dollar
Brazil Real
Mexico Peso
India Rupee

Antigua & Barbuda
Aruba
Barbados
Cayman Islands
Cuba
Curacao
Dominica

Grenada
Haiti
Jamaica
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines

Belize
Costa Rica
El Salvador
Honduras
Nicaragua
Panama

Bahamas
Bermuda
Mexico

Argentina
Brazil
Chile
Guyana
Paraguay
Peru
Uruguay

What's New at LAHT?
Follow Us On Facebook
Follow Us On Twitter
Most Viewed on the Web
Popular on Twitter
Receive Our Daily Headlines


  HOME | Science, Nature & Technology

Two-Drug Combination Reduces Colon Cancer 67%

BARCELONA – An international phase 1 clinical trial published on Monday and led by Barcelona’s Vall d’Hebron Hospital shows that a combination of two new antibodies that acts against the same protein reduces by 67 percent tumors in colorectal metastatic cancers that no longer respond to conventional treatment.

Josep Tabernero, head of Medical Oncology at Vall d’Hebron Hospital and director of the Vall d’Hebron Oncology Institute, explained to Efe that “this is important progress because we have showed this improvement for the first time in a clinical phase, although it is just one more step, it does not cure cancer, it only gives us more control time.”

The study, published in American Association for Cancer Research’s Cancer Discovery journal, demonstrated that the drug “Sym004,” a mixture of two antibodies that act against the EGFR protein, is effective in patients with advanced colorectal cancer who had become resistant to previous treatments with therapies inhibiting this protein.

This new drug opens the possibility for a treatment with better results in these advanced colon cancer cases. This is the second most common cancer type in the world with around 1.36 million new cases and 694,000 deaths every year.

 

Enter your email address to subscribe to free headlines (and great cartoons so every email has a happy ending!) from the Latin American Herald Tribune:

 

Copyright Latin American Herald Tribune - 2005-2020 © All rights reserved